JP2007508273A5 - - Google Patents

Download PDF

Info

Publication number
JP2007508273A5
JP2007508273A5 JP2006530156A JP2006530156A JP2007508273A5 JP 2007508273 A5 JP2007508273 A5 JP 2007508273A5 JP 2006530156 A JP2006530156 A JP 2006530156A JP 2006530156 A JP2006530156 A JP 2006530156A JP 2007508273 A5 JP2007508273 A5 JP 2007508273A5
Authority
JP
Japan
Prior art keywords
derivative
virus
polypeptide
spp
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006530156A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007508273A (ja
Filing date
Publication date
Priority claimed from GBGB0323968.8A external-priority patent/GB0323968D0/en
Application filed filed Critical
Publication of JP2007508273A publication Critical patent/JP2007508273A/ja
Publication of JP2007508273A5 publication Critical patent/JP2007508273A5/ja
Pending legal-status Critical Current

Links

JP2006530156A 2003-10-13 2004-10-11 免疫原性組成物 Pending JP2007508273A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0323968.8A GB0323968D0 (en) 2003-10-13 2003-10-13 Immunogenic compositions
PCT/EP2004/011621 WO2005039630A2 (en) 2003-10-13 2004-10-11 Immunogenic compositions

Publications (2)

Publication Number Publication Date
JP2007508273A JP2007508273A (ja) 2007-04-05
JP2007508273A5 true JP2007508273A5 (enExample) 2007-07-19

Family

ID=29559207

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006530156A Pending JP2007508273A (ja) 2003-10-13 2004-10-11 免疫原性組成物

Country Status (17)

Country Link
US (1) US20070212328A1 (enExample)
EP (1) EP1684802A2 (enExample)
JP (1) JP2007508273A (enExample)
KR (1) KR20060131749A (enExample)
CN (1) CN1893974A (enExample)
AU (1) AU2004283458A1 (enExample)
BR (1) BRPI0415315A (enExample)
CA (1) CA2541693A1 (enExample)
CO (1) CO5700789A2 (enExample)
GB (1) GB0323968D0 (enExample)
IL (1) IL174542A0 (enExample)
IS (1) IS8387A (enExample)
MA (1) MA28106A1 (enExample)
NO (1) NO20061911L (enExample)
RU (1) RU2006111849A (enExample)
WO (1) WO2005039630A2 (enExample)
ZA (1) ZA200602948B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003259827B2 (en) * 2002-08-12 2008-09-04 Dynavax Technologies Corporation Immunomodulatory compositions, methods of making, and methods of use thereof
DE602004025799D1 (de) * 2003-04-15 2010-04-15 Glaxosmithkline Llc Humane il-18 substitutionsmutanten und deren konjugate
JP2010503680A (ja) * 2006-09-14 2010-02-04 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア ヒトil−18による調節t細胞のモジュレーション
SE532249C2 (sv) * 2006-11-13 2009-11-24 Theravac Pharmaceuticals Ab Nya formuleringar av IL-18 för behandling av olika inflammatoriska sjukdomar genom vaccinering
US20090035360A1 (en) 2007-05-24 2009-02-05 Dominique Ingrid Lemoine Lyophilised antigen composition
WO2009108235A2 (en) * 2007-12-07 2009-09-03 Tekmira Pharmaceuticals Corporation Compositions and methods for modulating immune responses to nucleic acids
GB0810869D0 (en) * 2008-06-13 2008-07-23 Isis Innovation Vaccine adjuvant composition
TWI351288B (en) * 2008-07-04 2011-11-01 Univ Nat Pingtung Sci & Tech Cpg dna adjuvant in avian vaccines
CN102282155B (zh) 2008-12-02 2017-06-09 日本波涛生命科学公司 磷原子修饰的核酸的合成方法
EP2202298A1 (en) 2008-12-23 2010-06-30 Stichting Dienst Landbouwkundig Onderzoek Recombinant classical swine fever virus (CSFV) comprising a modified E2 protein and methods for generating said recombinant CSFV
AR074844A1 (es) * 2008-12-23 2011-02-16 Intervet Int Bv Composiciones farmaceuticas con saponinas
US9566323B2 (en) * 2009-06-19 2017-02-14 Eyegene Inc. Vaccine for cervical cancer
WO2011005761A1 (en) 2009-07-06 2011-01-13 Ontorii, Inc Novel nucleic acid prodrugs and methods use thereof
CN101814489A (zh) * 2010-03-02 2010-08-25 晶科电子(广州)有限公司 带有功能芯片的发光二极管封装结构及其封装方法
EP2399572A1 (en) 2010-06-22 2011-12-28 Sandoz AG Long-term storage of non-glycosylated recombinant human G-CSF
EP2734208B1 (en) 2011-07-19 2017-03-01 Wave Life Sciences Ltd. Methods for the synthesis of functionalized nucleic acids
WO2013082503A1 (en) * 2011-12-01 2013-06-06 Flow Pharma, Inc. Peptide particle formulation
US20140105970A1 (en) * 2011-12-01 2014-04-17 Flow Pharma, Inc. Adjuvant and antigen particle formulation
CN104661664B (zh) 2012-07-13 2020-07-03 波涛生命科学有限公司 手性控制
AU2013288048A1 (en) 2012-07-13 2015-01-22 Wave Life Sciences Ltd. Asymmetric auxiliary group
AU2013287630B2 (en) * 2012-07-13 2017-05-25 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant
EP3095459A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
EP3095460A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
US10144933B2 (en) 2014-01-15 2018-12-04 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
CN113278617A (zh) 2014-01-16 2021-08-20 波涛生命科学有限公司 手性设计
CN116327912A (zh) * 2021-12-23 2023-06-27 上海泽润生物科技有限公司 带状疱疹疫苗组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2268825C (en) * 1996-10-11 2006-04-18 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
US6291430B1 (en) * 1997-09-12 2001-09-18 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
JP2002510644A (ja) * 1998-04-03 2002-04-09 ユニバーシティ オブ アイオワ リサーチ ファウンデーション 免疫治療用オリゴヌクレオチドおよびサイトカインを用いる免疫系刺激のための方法および産物
JP2002513547A (ja) * 1998-05-07 2002-05-14 アクゾ・ノベル・エヌ・ベー ワクチン・アジュバントとしてのインターロイキン−18の使用
US6562798B1 (en) * 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
JP2002542203A (ja) * 1999-04-19 2002-12-10 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム ワクチン
US20010044418A1 (en) * 2000-03-10 2001-11-22 Shoshana Levy Treatment of allergies

Similar Documents

Publication Publication Date Title
JP2007508273A5 (enExample)
RU2006111849A (ru) Иммуногенные композиции
JP2007508272A5 (enExample)
RU2006111847A (ru) Вакцинные композиции, содержащие интерлейкин 18 и сапониновую адъювантную систему
Lacaille-Dubois Updated insights into the mechanism of action and clinical profile of the immunoadjuvant QS-21: A review
O'Hagan et al. Recent developments in adjuvants for vaccines against infectious diseases
Lahiri et al. Engagement of TLR signaling as adjuvant: towards smarter vaccine and beyond
AU764969B2 (en) Vaccines
CN100346829C (zh) 包含免疫刺激性寡核苷酸和母育酚的佐剂组合物
JP2014520807A5 (enExample)
WO1999052549A1 (en) Adjuvant compositions
AU2002221689A1 (en) Adjuvant composition comprising an immunostimulatory oligonucleotide and a tocol
JP2004511527A5 (enExample)
JP2006506441A5 (enExample)
JP5307859B2 (ja) ワクチン
CN1980691A (zh) 用于癌症免疫疗法的基于mage-3和ny-eso-1的多价疫苗
US8778356B2 (en) Vaccine
Arora et al. Oral mucosal immunization: Recent advancement and future prospects
Acevedo et al. Adjuvantes: Un componente esencial de las vacunas de Neisseria
Davis et al. Novel Strategies Using DNA for the Induction of Mucosal Immunity
HK1118481A (en) Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
HK1151231A (en) Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
HK1079088A (en) Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide